Sodium (Na+)/ Potassium (K+) ATPase alpha 1 (ATP1A1) subunit proteins identify new therapies for addressing blood clots and thrombosis.
Blood Clots - Causes Symptoms Diagnosis Treatment Prevention
An abnormal blood clot forms when there is damage to the lining of an artery or stagnation of blood in a vein; it obstructs the normal circulation of blood. A clot can form even in the absence of a cut.
An abnormal blood clot forms when there is damage to the lining of an artery or stagnation of blood in a vein; it obstructs the normal circulation of blood. A clot can form even in the absence of a cut.
‘Vascular thrombosis is the primary event in life threatening diseases such as myocardial infarction and stroke. Many current anti-platelet medications indicate they may cause severe side effects, e.g., excessive bleeding.’
“ATP1A1 heterozygosity did not affect platelet intracellular sodium concentration, suggesting that the observed anti-thrombotic phenotype is not due to a fall in the Na+/K+ ATPase pump function,” said Oliver Li, a second-year medical student at the Joan C. Edwards School of Medicine and lead author on the study. “ATP1A1 heterozygosity also reduced ADP-induced AKT activation in platelets, suggesting that ATP1A1 may participate in ADP-receptor mediated platelet activation.”
Blood Clot and Thrombosis
Based in the lab of Wei Li, M.D., Ph.D., Oliver Li and his co-authors presented the research last month at the International Society on Thrombosis and Haemostasis (ISTH) during its 2022 Congress, the leading international meeting in the field of thrombosis and hemostasis, held in London, England. Oliver Li was awarded the 2022 ISTH Congress Travel Award, which rewards abstracts of outstanding quality, for his presentation.Further study demonstrated that ATP1A1 forms a complex with P2Y12, a major ADP receptor on the platelet surface. Moreover, pretreatment of human platelets with Ouabain, an inhibitor of Na+/K+ ATPase, inhibited ADP-stimulated platelet aggregation in a dose-dependent manner. Intraperitoneal injection of Ouabain also significantly inhibited thrombosis in mice.
Rodrigo Aguilar, M.D., Renat Roytenberg, Hong Yue, M.D., Ph.D., Ellen Thompson, M.D., Sandrine Pierre, Ph.D., and Jiang Liu, M.D., Ph.D., also served as co-authors on the abstract. This work is supported by the Marshall University Institute Start Fund, the National Institutes of Health (R15HL145573 and R15HL145666), and the West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE) (P20GM103434).
Common Side Effects of Anticoagulants | Blood Thinners
The main side effect of anticoagulants or blood thinners is bleeding. Others include reduced platelet counts, allergic reactions and skin necrosis.
The main side effect of anticoagulants or blood thinners is bleeding. Others include reduced platelet counts, allergic reactions and skin necrosis.
Source-Eurekalert
Prostate Cancer may Precipitate the Risk of Developing Serious Blood Clots
Men with prostate cancer are found to have a 50% higher risk of developing serious and potentially fatal blood clots during the five years.
Men with prostate cancer are found to have a 50% higher risk of developing serious and potentially fatal blood clots during the five years.
COVID-19 Vaccine and Blood Clots � What�s the Link?
A new study reveals details on how COVID-19 vaccines have been linked to dangerous but incredibly rare blood clots.
A new study reveals details on how COVID-19 vaccines have been linked to dangerous but incredibly rare blood clots.
